[HT-02] Hot Topics 02「Disease modifying treatment and promissing biomarkers in primary tauopathies」

[HT-02-3] ARISE study: A Global Phase 2 trial of Tilavonemab in progressive supranuclear palsy

Nahome T. Fisseha (Japan Development, AbbVie GK)

Nahome Fisseha is Japan Asset Strategy Leader & Chief of Staff at AbbVie. He leads multidisciplinary teams that develop and commercialize pharmaceutical products across neuroscience, immunology, and virology therapeutic areas. Previously, Nahome served as global Scientific Director of Neuroscience Clinical Development at AbbVie working on early-to-late stage clinical programs including, in Alzheimer's disease. Parkinson's disease and progressive supranuclear palsy. He also served as precision medicine lead for neurodegenerative disorders, overseeing teams accountable for development of translational strategy and the delivery of biofluid, imaging and digital biomarkers. Nahome attended the University of Illinois at Chicago where he received his Doctor of Pharmacy degree and Drake University where he received his bachelor’s degree in Biochemistry, Cell and Molecular Biology.